Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Masuda

Showing results (261-270 of 298) with videos related to

Pageof 30
Sort By:
Blood Advances|April 2, 2026
IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programsYasuyo Ohguchi, Masahiko Ajiro, Daisuke Ogiya, et al.
Journal of Hematology & Oncology|April 5, 2022
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational studyYukari Tsubata, Takamasa Hotta, Kosuke Hamai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2019
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLCYoshihiro Ohue, Koji Kurose, Takahiro Karasaki, et al.
Journal of Thoracic Disease|June 17, 2024
Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancerTakeshi Masuda, Taizo Hirata, Tomohiro Sakamoto, et al.
Thoracic Cancer|October 17, 2024
Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational studyTakeshi Masuda, Yukari Tsubata, Kojirou Hata, et al.
JTO Clinical and Research Reports|May 8, 2025
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019LHideyuki Harada, Akito Hata, Masahiro Konno, et al.
BMC Pulmonary Medicine|June 30, 2022
Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancerNaokazu Watari, Kakuhiro Yamaguchi, Hiroaki Terada, et al.
Therapeutic Advances in Medical Oncology|July 28, 2022
Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, et al.
International Journal of Clinical Oncology|November 10, 2022
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study dataYukari Tsubata, Keita Kawakado, Kosuke Hamai, et al.
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Pageof 30

Showing results (261-270 of 298) with videos related to

Sort By:
Pageof 30
Blood Advances|April 2, 2026
IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programsYasuyo Ohguchi, Masahiko Ajiro, Daisuke Ogiya, et al.
Journal of Hematology & Oncology|April 5, 2022
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational studyYukari Tsubata, Takamasa Hotta, Kosuke Hamai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2019
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLCYoshihiro Ohue, Koji Kurose, Takahiro Karasaki, et al.
Journal of Thoracic Disease|June 17, 2024
Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancerTakeshi Masuda, Taizo Hirata, Tomohiro Sakamoto, et al.
Thoracic Cancer|October 17, 2024
Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational studyTakeshi Masuda, Yukari Tsubata, Kojirou Hata, et al.
JTO Clinical and Research Reports|May 8, 2025
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019LHideyuki Harada, Akito Hata, Masahiro Konno, et al.
BMC Pulmonary Medicine|June 30, 2022
Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancerNaokazu Watari, Kakuhiro Yamaguchi, Hiroaki Terada, et al.
Therapeutic Advances in Medical Oncology|July 28, 2022
Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, et al.
International Journal of Clinical Oncology|November 10, 2022
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study dataYukari Tsubata, Keita Kawakado, Kosuke Hamai, et al.
Cancer Medicine|November 10, 2023
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620LTakehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, et al.
Pageof 30